Despite the fact that the current literature data do not provide studies that directly compare PSMA-targeting radiopharmaceuticals to choline-labeled tracers, our meta-analysis demonstrated that the DR of PET with PSMA-targeting radiopharmaceuticals for HCC is not inferior to the one observed in PET with choline-labeled radiopharmaceuticals, as observed in a published meta-analysis on radiolabeled choline PET which reported a DR of 84% in 115 HCC patients [15]. Here, FOLH1 is linked to hepatocellular carcinoma.